ライフサイエンスコーパス: converting enzyme

1 of ADAM17, the membrane-associated TNF-alpha-converting enzyme.

2 he activity of the metalloprotease TNF-alpha-converting enzyme.

3 n of dipeptidyl peptidase IV and angiotensin-converting enzyme.

4 otons in even the most challenging of energy-converting enzymes.

5 cles homeobox 1 [EMX1], AK055957, endothelin-converting enzyme 1 [ECE1], phosphofructokinase [PFKP],

6 The angiotensin converting enzyme-1-angiotensin II-angiotensin AT(1) rec

7 Angiotensin-converting enzyme 2 (ACE-2), neprilysin (NEP), and plasm

8 howing crucial interactions with angiotensin-converting enzyme 2 (ACE2) and cross-reacting neutralizi

9 Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin

10 or SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, s

11 -19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane serine prot

12 and the human cellular receptor, angiotensin-converting enzyme 2 (ACE2) are both densely glycosylated

13 SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as its receptor to infect cel

14 Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 entry receptor.

15 12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 als

16 itu mapping revealed the highest angiotensin-converting enzyme 2 (ACE2) expression in the nose with d

17 s to utilize animal orthologs of angiotensin-converting enzyme 2 (ACE2) for cell entry.

18 which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into target cells.

19 This study compares angiotensin-converting enzyme 2 (ACE2) gene expression, which has be

20 ind to the cell surface receptor angiotensin converting enzyme 2 (ACE2) glycoprotein and facilitate h

21 Angiotensin-converting enzyme 2 (ACE2) has been identified as the ho

22 nformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction in vitro.

23 Angiotensin-converting enzyme 2 (ACE2) is a potent negative regulato

24 Angiotensin-converting enzyme 2 (ACE2) is an entry receptor for seve

25 S-CoV-2 spike protein binding to angiotensin-converting enzyme 2 (ACE2) is critical for viral cell en

26 Although angiotensin-converting enzyme 2 (ACE2) is crucial for SARS-CoV-2 to

27 In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovasc

28 Angiotensin-converting enzyme 2 (ACE2) is the canonical cell surface

29 coronavirus 2 (SARS-CoV-2) binds angiotensin-converting enzyme 2 (ACE2) on host cells to initiate ent

30 hrough binding of the virus with angiotensin converting enzyme 2 (ACE2) on the cell membrane.

31 reported that the human receptor angiotensin-converting enzyme 2 (ACE2) plays a key role for capturin

32 Angiotensin converting enzyme 2 (ACE2) plays an important role in in

33 ly, we have shown that loss of angiotensin-I converting enzyme 2 (ACE2) promotes the ACE/angiotensin-

34 were demonstrated, one being on angiotensin-converting enzyme 2 (ACE2) protein which is Severe Acute

35 navirus canonically utilizes the angiotensin-converting enzyme 2 (ACE2) receptor and the serine prote

36 spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a prelude to vira

37 (CDR) H3, and competes with the angiotensin-converting enzyme 2 (ACE2) receptor because of steric hi

38 enic mice expressing the human angiotensin I-converting enzyme 2 (ACE2) receptor driven by the cytoke

39 pike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a single experime

40 V-2) spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor is a promising thera

41 ), the hexapeptide YKYRYL on the angiotensin-converting enzyme 2 (ACE2) receptor, and its inhibitory

42 ered to stably express the human angiotensin-converting enzyme 2 (ACE2) receptor, but stably introduc

43 ceptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor.

44 es-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors.

45 oth cellular heparan sulfate and angiotensin-converting enzyme 2 (ACE2) through its receptor-binding

46 Infection of human angiotensin-converting enzyme 2 (ACE2) transgenic mice and Syrian ha

47 ike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affinity.

48 at the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than doe

49 rthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2)(4).

50 RS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host pro

51 ers host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or not renin-ang

52 - gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to und

53 piratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small

54 SARS-CoV-2) viral association to angiotensin-converting enzyme 2 (ACE2), its main host receptor, and

55 idate vaccine antigen that binds angiotensin-converting enzyme 2 (ACE2), leading to virus entry.

56 We further identified Ang converting enzyme 2 (ACE2), the major negative regulator

57 a dose-dependent upregulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, in

58 trate that, in addition to human angiotensin-converting enzyme 2 (ACE2), the Spike glycoprotein of SA

59 receptor for SARS-CoV-2 binding, angiotensin-converting enzyme 2 (ACE2), was not detected by messenge

60 main (RBD) and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cros

61 ke protein and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cros

62 tion of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper (nasal) and

63 es dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site.

64 -CoV recognize the same receptor-angiotensin-converting enzyme 2 (ACE2)-in humans(3,4).

65 ope that partially overlaps with angiotensin-converting enzyme 2 (ACE2)-interacting sites on the CoV-

66 into its interactions with the angiotensin I-converting enzyme 2 (ACE2)-solute carrier family 6 membe

67 ), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).

68 otein and the host cell receptor angiotensin-converting enzyme 2 (ACE2).

69 CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2).

70 ection is mediated by binding to angiotensin-converting enzyme 2 (ACE2).

71 BD)) from interacting with human angiotensin-converting enzyme 2 (ACE2).

72 rus (SARS-CoV-2) that uses human angiotensin-converting enzyme 2 (hACE2) as the entry receptor.

73 transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cytokeratin 18

74 nd optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutralize severe

75 In response to human receptor angiotensin-converting enzyme 2 (hACE2), S opens sequentially into t

76 ogue of its human entry receptor angiotensin-converting enzyme 2 (hACE2).

77 The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that selectively c

78 are compared with those between angiotensin-converting enzyme 2 and RBD complexes.

79 spective, we examine the role of angiotensin converting enzyme 2 as the receptor for severe acute res

80 according to computed S protein-angiotensin-converting enzyme 2 binding free energy changes.

81 Arteriolar angiotensin-converting enzyme 2 endothelial expression was lower in

82 e viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) provide the firs

83 The role of angiotensin converting enzyme 2 has expanded from regulating the ren

84 An angiotensin-converting enzyme 2 immunohistochemical H-score was comp

85 ive transcytosis and that murine angiotensin-converting enzyme 2 is involved in brain and lung uptake

86 n fetal growth restriction in an angiotensin-converting enzyme 2 knockout mouse model characterized b

87 Angiotensin-converting enzyme 2 myocardial expression did not differ

88 ycosylated S trimers bind to the angiotensin-converting enzyme 2 receptor and mediate entry of virion

89 lay between virus binding to the angiotensin-converting enzyme 2 receptor and the impact this action

90 lycoprotein (S protein) and host angiotensin-converting enzyme 2 receptor following mutations.

91 protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells.

92 which invades cells through the angiotensin-converting enzyme 2 receptor.

93 2) and mice expressing the human angiotensin-converting enzyme 2 receptor.

94 Although angiotensin-converting enzyme 2 serves as the portal for infection,

95 Recently, angiotensin converting enzyme 2 was identified as a primary receptor

96 Human angiotensin-converting enzyme 2(ACE2) was identified as the entry re

97 ACE2 (angiotensin-converting enzyme 2) and Ang 1-7 (angiotensin 1-7) are e

98 ACE2 (angiotensin-converting enzyme 2) and NEP (neprilysin) induce the alt

99 is binding of the virus to ACE2 (angiotensin-converting enzyme 2) on the airway epithelium.Objectives

100 ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmembrane proteas

101 ade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothel

102 Background Angiotensin-converting enzyme 2, a target of severe acute respirator

103 nced BP, decreased expression of angiotensin converting enzyme 2, and increased expression of the Na(

104 The counter-regulatory axis, Angiotensin Converting Enzyme 2, Angiotensin-(1-7), Mas receptor (AC

105 approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic domain.

106 binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformational changes t

107 s on host proteins, most notably angiotensin-converting enzyme 2, might also provide worthwhile imagi

108 riggered by SARS-CoV-2 depend on angiotensin-converting enzyme 2, serine protease, virus replication,

109 ngiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor

110 rimer immunoglobulin G inhibited angiotensin-converting enzyme 2-spike protein binding to a greater d

111 ldosterone system (RAAS) through angiotensin-converting enzyme 2.

112 eric spike glycoprotein to human angiotensin-converting enzyme 2.

113 ng of the viral spike protein to angiotensin-converting enzyme 2.

114 the binding of spike protein to angiotensin-converting enzyme 2.

115 s of the receptor for the virus, angiotensin converting enzyme 2.

116 unctional receptor of the virus, angiotensin-converting enzyme 2.

117 The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- Co

118 genic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry receptor.

119 s to identify factors related to angiotensin-converting enzyme-2 (ACE2) expression within bronchial e

120 inding domain that engages human angiotensin-converting enzyme-2 (ACE2).

121 SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2).

122 ough direct interaction with the angiotensin converting enzyme (ACE) 2 protein at the surface of many

123 hanges in serum, lung and kidney angiotensin-converting enzyme (ACE) activity, established in F1 offs

124 l pressure and 19% inhibition of angiotensin converting enzyme (ACE) activity.

125 Angiotensin-converting enzyme (ACE) affects blood pressure.

126 1h (STP-C1) had the most potent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP

127 drolysates (WPHs) obtained had angiotensin-I-converting enzyme (ACE) and dipeptidyl peptidase IV (DPP

128 ducts (AGEs) and the activity of angiotenisn-converting enzyme (ACE) and the enzyme acetylcholinester

129 Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metal

130 Angiotensin-converting enzyme (ACE) can hydrolyze many peptides and

131 Angiotensin-converting enzyme (ACE) converts angiotensin I into the

132 Angiotensin II, converted by angiotensin-converting enzyme (ACE) from angiotensin I and metaboliz

133 The peptide inhibition of the angiotensin I-converting enzyme (ACE) from its default biochemical con

134 HF history and treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin recepto

135 To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in patients wi

136 Angiotensin Converting Enzyme (ACE) Inhibitor treatment (aHR=1.69, 9

137 o decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema

138 ree most common medications were angiotensin-converting enzyme (ACE) inhibitors (17.9%), antidepressa

139 eral therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and angiotensin recep

140 nventional therapy consisting of angiotensin-converting enzyme (ACE) inhibitors or angiotensin recept

141 s study was to determine whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin recept

142 duced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor

143 analysis to assess the effect of angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor

144 f them were found identical to angiotensin I-converting enzyme (ACE) inhibitors, antioxidant, antimic

145 Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II recept

146 peptides with alpha-amylase and angiotensin converting enzyme (ACE) inhibitory activities were succe

147 H), degree of hydrolysis (DH), angiotensin-I converting enzyme (ACE) inhibitory activity of hydrolysa

148 The angiotensin I-converting enzyme (ACE) inhibitory activity of protein h

149 Three angiotensin converting enzyme (ACE) inhibitory peptides, IPP (0.42-0

150 rated higher antioxidative and angiotensin-1 converting enzyme (ACE) inhibitory potential compared to

151 nt amino acid compositions and angiotensin I-converting enzyme (ACE) inhibitory potentials.

152 Angiotensin-I converting enzyme (ACE) is a zinc metalloprotease consis

153 Targeted overexpression of angiotensin-converting enzyme (ACE), an amyloid-beta protein degradi

154 e measured the mRNA of renin and angiotensin-converting enzyme (ACE), and found both were sharply inc

155 in (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor

156 has been proposed: imbalance of angiotensin converting enzymes (ACE)1 and ACE2 (ACE2 being the sever

157 ng a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-recep

158 min excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs th

159 sin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the risk of coron

160 Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-recept

161 ds and phenolic compounds, DPPH, angiotensin-converting-enzyme (ACE) inhibitory activity, fatty acids

162 nd alpha-glucosidase inhibition, angiotensin-converting-enzyme (ACE)-inhibition, antioxidant and prot

163 patients known to be tolerant to angiotensin-converting-enzyme (ACE)-inhibitors were randomly assigne

164 tic biomarkers (eg, lysozyme and angiotensin-converting enzyme [ACE]) are lacking in high sensitivity

165 express the SARS-CoV-2 receptors angiotensin converting enzyme (ACE2) and transmembrane protease/seri

166 ntative information about use of angiotensin-converting enzyme (ACEs) inhibitors or angiotensin II re

167 of the renin-angiotensin system-angiotensin-converting enzymes (ACEs) ACE and ACE2, angiotensin II (

168 These MPs exhibited angiotensin-converting enzyme activity and upregulated AT1 receptors

169 This enhanced TNF-alpha-converting enzyme activity significantly increases the r

170 atal offspring growth and tissue angiotensin-converting enzyme activity were programmed by paternal l

171 relevant in the PFC, where D-serine and its converting enzyme are highly expressed.

172 henYiQi Pills using thrombin and angiotensin converting enzyme as "quality biomarkers".

173 rophil cytoplasmic antibody, and angiotensin-converting enzyme blood test results were negative.

174 opril) and thus was dependent on angiotensin-converting enzyme catalytic activity.

175 ween redox enzymes and electrodes is key for converting enzyme-catalyzed reactions into electrochemic

176 chymase-dependent rather than an angiotensin converting enzyme-dependent mechanism.

177 Metalloproteases, including endothelin-converting enzyme (ECE)-1 and -2, reside within these ve

178 m signaling pathways that induce angiotensin-converting enzyme expression and endothelial dysfunction

179 nd 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dysfunction, s

180 , also known as interleukin-1beta (IL-1beta)-converting enzyme (ICE), regulates antimicrobial host de

181 ng to the human receptor protein angiotensin-converting enzyme II (ACE2).

182 nd upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs.

183 ls correlated with the activity of vitamin A-converting enzymes in mesenteric lymph node dendritic ce

184 tor receptor phosphorylation and angiotensin-converting enzyme induction.

185 Finally, angiotensin-converting enzyme inhibition (captopril) normalized bloo

186 n to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with

187 al albuminuria during fixed dose angiotensin-converting enzyme inhibition.

188 regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin recept

189 medical therapy, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II recept

190 10 phenotype was reversed by the angiotensin-converting enzyme inhibitor (lisinopril) and thus was de

191 Pairwise matching (1:1) of the angiotensin-converting enzyme inhibitor and angiotensin receptor blo

192 s losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wound healing i

193 ction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peri

194 -aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor b

195 lomerular disease with either an angiotensin-converting enzyme inhibitor or an angiotensin type 1 rec

196 d been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin II receptor b

197 axagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor b

198 systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

199 enal disease classification, and angiotensin converting enzyme inhibitor or angiotensin receptor bloc

200 ts on active therapy with either angiotensin-converting enzyme inhibitor or beta-blockers experienced

201 ophospholipids was inhibited by the TNFalpha converting enzyme inhibitor TAPI-0 indicating normal pro

202 It is an angiotensin-converting enzyme inhibitor that operates via chelating

203 ntify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves renal and l

204 ceptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Globa

205 ngs support the possibility that angiotensin-converting enzyme inhibitor treatment might limit PEC ac

206 , birth weight, premature birth, angiotensin-converting enzyme inhibitor use, angiotensin receptor bl

207 n (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiotensin II rece

208 n receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin receptor blo

209 editary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioedema.

210 nts were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

211 ical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

212 5 mg/day, a standard dose of an angiotensin converting enzyme inhibitor/angiotensin receptor blocker

213 subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

214 Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Glob

215 proteinase/TACE (tumor necrosis factor-alpha-converting enzyme) inhibitor GM6001 was ineffective.

216 giotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin rece

217 ithin 30 days of initiating ACE (angiotensin-converting enzyme) inhibitor or angiotensin II receptor

218 0.97 [95% CI, 0.69-1.35]), ACE (angiotensin-converting enzyme) inhibitor or angiotensin receptor blo

219 t heart failure medication (ACE [angiotensin-converting enzyme] inhibitor or angiotensin II receptor

220 enin-angiotensin system, such as angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin re

221 The association between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin rece

222 anistic evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II re

223 ontinued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II re

224 ced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin recepto

225 o -0.02; P = 0.01), specifically angiotensin-converting enzyme inhibitors (ACEIs) (beta = -1.66; 95%

226 The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-rec

227 Angiotensin-converting enzyme inhibitors (ACEIs) may retard the deve

228 lcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respectively.

229 It has been hypothesized that angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin recepto

230 (OR = 0.70, 95% CI 0.54-0.92) or angiotensin-converting enzyme inhibitors (OR = 0.69, 95% CI 0.52-0.9

231 which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin recept

232 Hg (95% CI, -7.27 to -2.16) for angiotensin-converting enzyme inhibitors and -3.07 mm Hg (95% CI, -4

233 years for the patients receiving angiotensin-converting enzyme inhibitors and 2.87 per 100 person-yea

234 each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor

235 rugs in the same year, including angiotensin-converting enzyme inhibitors and angiotensin receptor bl

236 y aimed to compare the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor bl

237 sion, medical therapy, including angiotensin-converting enzyme inhibitors and angiotensin receptor bl

238 und high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin-receptor bl

239 be unsafe in pregnancy, such as angiotensin-converting enzyme inhibitors and statins, should be disc

240 de-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-

241 ction fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-documented.

242 ients receiving beta-blockers or angiotensin-converting enzyme inhibitors had a higher risk of develo

243 the index date, those receiving angiotensin-converting enzyme inhibitors had a higher risk of sepsis

244 addition, the patients receiving angiotensin-converting enzyme inhibitors had a higher risk of septic

245 tes of sepsis and mortality than angiotensin-converting enzyme inhibitors in the patients with chroni

246 ), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor

247 idence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blo

248 ortal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blo

249 e pulmonary disease who received angiotensin-converting enzyme inhibitors or angiotensin receptor blo

250 ing insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blo

251 roteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blo

252 responsive to monotherapy with angiotensin-I converting enzyme inhibitors or angiotensin-II receptor

253 ulation where monotherapy with angiotensin-I converting enzyme inhibitors or angiotensin-II receptor

254 cribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-receptor blo

255 s study was to determine whether angiotensin-converting enzyme inhibitors or beta-blockers reduce the

256 der the use of beta-blockers and angiotensin-converting enzyme inhibitors that are symptomatic and un

257 ced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that inhibit bot

258 hours, and rapid up-titration of angiotensin-converting enzyme inhibitors, angiotensin receptor block

259 zide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor block

260 No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-receptor block

261 Suitable genetic proxies for angiotensin-converting enzyme inhibitors, beta-blockers, and calcium

262 ed lipid-lowering medication and angiotensin-converting enzyme inhibitors, especially if they had car

263 angiotensin receptor blockers or angiotensin-converting enzyme inhibitors.

264 or thiazide-like diuretics over angiotensin-converting enzyme inhibitors.

265 hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.

266 trials of beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin receptor blocke

267 n of statins, beta-blockers, and angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

268 ncluding statins, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

269 74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

270 ts of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

271 of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

272 tment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

273 n rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

274 etter primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarctio

275 initiation of beta blockers and angiotensin-converting-enzyme inhibitors (ACE-Is) or angiotensin rec

276 duction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor block

277 nists, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, serotonin-specific reuptak

278 r blockers (beta-blockers), ACE (angiotensin-converting enzyme) inhibitors and ANG (angiotensin) II b

279 ults Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angiotensin recep

280 olysis and negatively affected angiotensin I-converting enzyme inhibitory activity of fermented lenti

281 tivity (antioxidant effect and angiotensin I-converting enzyme inhibitory activity), rheological, and

282 ting relevant bioactivities like angiotensin converting enzyme inhibitory activity, antioxidant activ

283 ated via death domain-like interleukin 1beta-converting enzyme inhibitory protein), an apoptosis inhi

284 loprotease TACE (tumor necrosis factor alpha converting enzyme) is responsible for producing active E

285 angial cells for the presence of angiotensin-converting enzyme on their surface using angiotensin I (

286 ogically antagonizing either the angiotensin-converting enzyme or the receptor for angiotensin II att

287 ibit the activity of neprilysin, angiotensin-converting enzyme, or aminopeptidase N, respectively.

288 vidence for therapeutic roles of angiotensin-converting enzyme-overexpressing macrophages in preservi

289 mpact of selective and transient angiotensin-converting enzyme overexpression on macrophage behaviour

290 onavirus 2 (SARS-CoV-2) receptor angiotensin-converting enzyme receptor type-2 (ACE2) and can be infe

291 hies, neurological disorders, and cancer, PI-converting enzymes represent potential targets for drug-

292 )CD11b(+) DC subset expressing the vitamin A-converting enzyme retinaldehyde dehydrogenase and specia

293 D(+), NAMPT regulates the activity of NAD(+)-converting enzymes, such as CD38, poly-ADP-ribose polyme

294 mammalian metalloproteases such as TNFalpha converting enzyme (TACE) (Ki = 4.45 +/- 0.48 muM).

295 and tumor necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) are prominent membrane-anchored

296 sTNF is generated by TNF-alpha converting enzyme (TACE) proteolytic release of the tran

297 g1TIII inhibitor tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17), also ameliorates the ne

298 ytic activity of tumor necrosis factor alpha-converting enzyme (TACE; ADAM17, CD156b), the metallopro

299 o associated with a reduction of angiotensin-converting enzyme type 2 (ACE2) and an increase in a dis

300 One such effector was angiotensin-converting enzyme, which is a member of the renin-angiot